11th RSC/SCI Symposium on Kinase Inhibitor Design
Event
11th RSC/SCI Symposium on Kinase Inhibitor Design
Dates
Monday 12 – Tuesday 13 May, 2025 – A date for your diary!
Place
Royal College of Physicians of Edinburgh, Edinburgh
Synopsis
With more than 100 clinically approved small molecules, the field of kinase modulation continues to attract significant investment from the drug discovery community and attention from academia. The 11th RCS-BMCS/SCI symposium on kinase inhibitor design will encompass plenary lectures on emerging topics and case studies of ongoing programmes as well as successful past programmes. A range of topics including brain penetrant and inhaled kinase inhibitors, kinase chemical probes, allosteric modulators, targeted kinase protein degradation and kinase inhibition for non-oncology indications will be covered, along with views and perspectives on the future of kinase modulator research.
Keynote Speakers
Sir Philip Cohen – University of Dundee
Professor Gunda Georg – University of Minnesota, USA
Professor Stefan Laufer – Eberhard Karls University of Tübingen, Germany
Confirmed Speakers
Andreas Blum – Merck, Germany
Helen Boffey – ALBORADA Drug Discovery Institute, UK
Chiara Borsari – University of Milan, Italy
Charlotte Griffiths-Jones – Astex
Andreas Lerchner – Novartis, Switzerland
William McCoull – AstraZeneca, UK
Simon Nicolle – GSK
Magnus Nilsson – AstraZeneca, Sweden
Ulrike Obst Sander – Roche, Switzerland
Alexander Pautsch – Boehringer Ingelheim, Germany
Bradley Sherborne – Pharmaron
Progamme – Day 1
| 09:15 | Registration and refreshments |
|---|---|
| 09:55 | Opening remarks |
| 10:00 | Keynote Speaker Kinase inhibitors; major drugs for the treatment of disease in the 21st century Sir Phillip Cohen, University of Dundee |
| 10:45 | Discovery of londamocitinib (AZD4604), a potent and selective inhaled JAK1 inhibitor in clinical development Dr Magnus Nilsson, AstraZeneca |
| 11:15 | Refreshments, exhibition and posters |
| 11:45 | Discovery and Optimization of Macrocyclic Allosteric Inhibitors of the MET Kinase Ulrike Obst Sander, Roche |
| 12:15 | (Virtual) Chemical Strategies to Selectively Target Kinases Dr Chiara Borsari, University of Milan |
| 12:45 | Lunch, exhibition and posters |
| 13:45 | Development of Brain Penetrant NUAK1 Inhibitors and Chemical Probes for In Vivo Target Validation Helen Boffey, ALBORADA Drug Discovery Institute, University of Cambridge |
| 14:15 | Highly Optimised CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations William McCoull, AstraZeneca |
| 14:45 | Exploring novel therapeutic opportunities by targeting CLK-family kinases Dr Andreas Lerchner, Novartis |
| 15:15 | Flash Poster Presentations |
| 15:45 | Network reception, exhibition and posters |
Programme – Day 2
| 09:30 | Registration and refreshments |
|---|---|
| 10:00 | Keynote Speaker First disclosure of an MKK4 inhibitor for treatment of liver disease Professor Stefan Laufer, Eberhard Karls University of Tübingen |
| 10:45 | Agonizing over Inhibitors: the atypical story and properties of HC-7366 Bradley Sherborne, Pharmaron |
| 11:15 | Refreshments, exhibition and posters |
| 11:45 | Discovery of a potent, zwitterionic and orally bioavailable chemical probe for ketohexokinase Alexander Pautsch, Boehringer Ingelheim |
| 12:15 | The discovery of indazole inhibitors of oncogenic KIT mutations for the treatment of GIST Andreas Blum, Merck |
| 12:45 | Lunch, exhibition and posters |
| 13:45 | Phenotype-led identification of IL-10 upregulators in human CD4+ T-cells and elucidation of their pharmacology as highly selective CDK8/CDK19 inhibitors Simon Nicolle, GSK |
| 14:15 | Short talk - Conformational selection by dasatinib for phosphorylated Y394 Lck provides a new mechanism to target the regulation of Lck-mediated immune response and new structures to support drug discovery. Samantha Rickard, The University of Auckland |
| 14:30 | Short talk - Leveraging Generative Machine Learning Models to Discover State-Specific Inhibitors Across the Kinome Rayees Rahman, Harmonic Discovery |
| 14:45 | Refreshments, exhibition and posters |
| 15:15 | Application of fragment based drug discovery to kinase inhibition Charlotte Griffiths-Jones, Astex |
| 15:45 | (Virtual) Keynote Speaker Discovery of kinase inhibitors and degraders for male contraception Professor Gunda Georg, University of Minnesota |
| 16:30 | Closing remarks |
| 16:40 | Close |
Registration
Please click here to register.
RSC/SCI Member Early bird £310
Non-Member Early bird £390
RSC Student Member Early bird £145
Student Non-Member Early bird £215
Early bird registration closes Midnight (GMT) Friday 28th March, 2025
RSC Member £360
Non-Member £440
RSC Student Member £195
Student Non-Member £265
Registration closes Midnight (GMT) 2nd May, 2025
Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.
Abstracts
Abstract submissions deadline has now passed.
Exhibitors
Sponsors
Sponsorship/Exhibition Opportunities
Bookings to sponsor or exhibit at the meeting are now open, click here to register.
Exhibition Package includes (£1,000):
– One stand personnel with access to technical sessions
– A six-foot trestle table and chair(s)
– Electrical and Wi-Fi access
– Your logo and full promotional page in the pdf of the delegate handbook
– Your logo in the rolling slides, shown during the breaks
– Any additional stand personnel will have to be booked as delegates
Sponsorship includes
– Your logo in the pre-event announcements
– Your logo in the pdf of the delegate handbook
– Your logo in the rolling slides, shown during the breaks
– Your logo included in the communication email to delegates
Important links and downloads
X hashtag – #Kinase2025
Organising Committee
Helen Aylott, Redx Pharma
John Cumming, Roche
Ray Finlay, AstraZeneca
Pascal Savy, Isomorphic Labs
Asier Unciti-Broceta, University of Edinburgh
Secretariat Contact and Further Information
Hg3 Conferences Ltd
E-mail
